CTLA4 and neoplasm: Then, Jafarnejad et al. [99] included a detailed model for APC antigen presentation, and Milberg et al. [111] proved that this platform was able to predict longitudinal tumor size profiles and the number of patients showing partial or complete response for anti-PD1 and anti-CTLA4 combinations in melanoma.